Ultrasound to predict Guselkumab response in Crohn's disease
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have moderate to severe Crohn's disease that is newly diagnosed or has come back.
- You have not had any abdominal surgery.
- You are not allergic to Guselkumab or the contrast agent used for ultrasound.
- You do not have active infections, tuberculosis, or severe liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses intestinal ultrasound to see if vedolizumab can heal the gut in people recently diagnosed with Crohn's disease. It aims to find early signs that the treatment is working.
This study tests whether an ultrasound score (called VAT) combined with another ultrasound score (IUS) can predict how well anti-TNF medications (like infliximab) work for people with inflammatory bowel disease. If you are starting a new anti-TNF treatment, this study may help doctors understand if the medication will be effective for you.
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
This study tests whether guselkumab (a targeted drug) can effectively treat Crohn's disease in the ileum (last part of the small intestine). You will have ultrasound scans and blood tests to measure your response, which may help find the right dose and monitor for bowel healing.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
Hear when a new Crohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.